drugset / Trial / NCT03769662

Follow on Extension of XT-150-1-0201

NCT03769662 ↗

Phase 1 Completed 16 enrolled Xalud Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

XT-150 safety and efficacy in severe osteoarthritic pain.

Timeline

Start
2019-03-20
Primary completion
2019-10-30
Completion
2019-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject XT-150 Other / unclassified — Other

Indications